| Literature DB >> 29927354 |
Brandy E Wade1, Jingru Zhao1, Jing Ma1, C Michael Hart1, Roy L Sutliff1.
Abstract
Pulmonary hypertension (PH) is a clinical disorder characterized by sustained increases in pulmonary vascular resistance and pressure that can lead to right ventricular (RV) hypertrophy and ultimately RV failure and death. The molecular pathogenesis of PH remains incompletely defined, and existing treatments are associated with suboptimal outcomes and persistent morbidity and mortality. Reports have suggested a role for the ubiquitin proteasome system (UPS) in PH, but the extent of UPS-mediated non-proteolytic protein alterations during PH pathogenesis has not been previously defined. To further examine UPS alterations, the current study employed C57BL/6J mice exposed to normoxia or hypoxia for 3 weeks. Lung protein ubiquitination was evaluated by mass spectrometry to identify differentially ubiquitinated proteins relative to normoxic controls. Hypoxia stimulated differential ubiquitination of 198 peptides within 131 proteins ( p < 0.05). These proteins were screened to identify candidates within pathways involved in PH pathogenesis. Some 51.9% of the differentially ubiquitinated proteins were implicated in at least one known pathway contributing to PH pathogenesis, and 13% were involved in three or more PH pathways. Anxa2, App, Jak1, Lmna, Pdcd6ip, Prkch1, and Ywhah were identified as mediators in PH pathways that undergo differential ubiquitination during PH pathogenesis. To our knowledge, this is the first study to report global changes in protein ubiquitination in the lung during PH pathogenesis. These findings suggest signaling nodes that are dynamically regulated by the UPS during PH pathogenesis. Further exploration of these differentially ubiquitinated proteins and related pathways can provide new insights into the role of the UPS in PH pathogenesis.Entities:
Keywords: hypoxia; proteasome; ubiquitin
Year: 2018 PMID: 29927354 PMCID: PMC6146334 DOI: 10.1177/2045894018788267
Source DB: PubMed Journal: Pulm Circ ISSN: 2045-8932 Impact factor: 3.017
Fig. 1.Chronic hypoxia exposure alters lung protein ubiquitination and proteasome activity. A) Volcano plot comparing total changes in ubiquitination of peptides in the mouse lung after hypoxia exposure. The dashed lines indicate the fold change (≥±1.50) and significance (p < 0.05) thresholds. Colored dots represent individual ubiquitinated peptides: peptides represented by blue dots do not meet the significance criteria, peptides represented by green dots demonstrate decreased ubiquitination in hypoxia, and peptides represented by red dots have increased ubiquitination in hypoxia. B) Heat map comparing ubiquitinated peptides in normoxia and hypoxia. Columns represent individual samples; rows represent individual ubiquitinated peptides. C) Ubiquitin chains removed from proteins were analyzed by MS to identify significant changes in ubiquitin chain linkage. D) Total ubiquitin removed from proteins was quantified by summing ubiquitin peptide areas, a measurement of peptide quantity, then normalized to normoxic samples. E and F) Chymotrypsin-like proteasome activity assay was measured in mouse lung (E) and mouse pulmonary artery (F). N=5. *p < 0.05 compared to normoxia K11, #p < 0.05 compared to normoxia K48. Results are plotted as mean ± SEM.
Fig. 2.Ubiquitin modification in pathways commonly associated with PH. AmiGO 2 was used to compile an annotated index of associated gene ontologies for PH associated pathways. Each bar represents the percent of total peptides (filled bars) or proteins (open bars) with significant ubiquitin modifications found within each of the indicated gene ontologies.
Summary of total ubiquitin modifications identified in PH-related pathways.
| Proteins | Peptides | |
|---|---|---|
| Total | 131 | 198 |
| PH Pathways | 68 | 102 |
| % of Total | 51.9% | 51.5% |
Fig. 3.Protein ubiquitination in PH pathway functional groups. Gene ontologies within each PH pathway selected were grouped by function. Peptides (open bars) or proteins (filled bars) within each functional group are represented as percent of the proteins/peptides in that PH pathway. Functional groups within A) Cell Cycle, B) Cell Proliferation, C) Cell Migration, D) Calcium Signaling, and E) Cell Death are presented.
Fig. 4.Ubiquitinated proteins associated with multiple PH pathways. A) The chord diagram demonstrates the overlapping roles of proteins with hypoxia-induced alterations in ubiquitination that function in 3 or more PH pathways. Each protein on the left side of the circle represents a protein that functions in 3 or more PH pathways. PH pathways are on the right side of the circle. B) Graphical representation of protein-interaction network performed on proteins that function in 3 or more PH pathways generated using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins). Solid lines between protein nodes (ovals) indicate protein-protein interactions identified from both experimental data and curated databases. Dashed lines between protein nodes represent protein-protein interactions identified through experimental data only. Anxa2 = Annexin A2, App = Amyloid-beta A4 protein, Calm1 = Calmodulin, Cav1 = Caveolin-1, Cd34 = Hematopoietic progenitor cell antigen CD34 isoform 2 precursor, Cdc42 = Cell division control protein 42 homolog isoform 1 precursor, Epha2 = Ephrin type A receptor 2 precursor, Ilk = Integrin linked protein kinase, Jak1 = Tyrosine-protein kinase JAK1, Kras = GTPase KRas, Lmna = Prelamin-A/C, Pdcd6ip = Programmed cell death 6-interacting protein, Pfn1 = Profilin-1, Prkch = Protein kinase C eta type, Rac1 = Ras-related C3 botulinum toxin substrate 1, Rhoa = Transforming protein RhoA, and Ywhah = 14-3-3 protein eta.
Proteins with roles in three or more PH pathways.
| 8/9 Pathways | Modifications Identified |
|---|---|
| caveolin 1 isoform 1 (Cav1) | (K26) (K26; K30) (K26; M32OX) (K30) (K30; K39) (K30; M32OX) (K30; M32OX; K39) |
|
| |
| transforming protein RhoA (RhoA) | (C107CM; K118) (C107CM; K119) |
|
| |
| cell division control protein 42 homolog isoform 1 precursor (Cdc42) | (K131) (K133) |
|
| |
| prelamin A/C isoform A precursor (Lmna) | (K135) |
|
| |
| annexin A2 (Anxa2) | (K115) (K80) |
| calmodulin (Calm1) | (K78) |
| ephrin type A receptor 2 precursor (Epha2) | (K579) |
| GTPase KRas (Kras) | (K128) |
| hematopoietic progenitor cell antigen CD34 isoform 2 precursor (Cd34) | (N330DIA; K349) |
| ras-related C3 botulinum toxin substrate 1 precursor (Rac1) | (K147) |
|
| |
| 14-3-3 protein eta (Ywhah) | (K50) |
| integrin-linked protein kinase (Ilk) | (K154; M155OX) |
| profilin-1 (Pfn1) | (K126) (K54) |
| programmed cell death 6-interacting protein isoform 1 (Pdcd6ip) | (K506) |
| protein kinase C eta type (Prkch) | (K36) |
| tyrosine protein kinase JAK1 (Jak1) | (K227) |
| amyloid beta A4 protein isoform 1 precursor (App) | (K751; Q754DIA) |
|
| |
| activated CDC42 kinase 1 isoform 1 (Tnk2) | (K131) |
| tyrosine protein kinase HCK isoform p59Hck (Hck) | (K38) |
| apolipoprotein A I preproprotein (Apoa1) | (K205) |
| claudin-18 isoform A2.1 (Cldn18) | (K229) |
| hemoglobin subunit beta-1 (Hbb-b1) | (K121) |
| hepatocyte growth factor regulated tyrosine kinase substrate isoform 1 (Hgs) | (C75CM; K86) |
| neuronal membrane glycoprotein M6-a isoform 1 (Gpm6a) | (K257) |
| peptidyl-prolyl cis-trans isomerase D (Ppid) | (C275CM; C282CM; K283) |
| peroxiredoxin-6 (Prdx6) | (K97) (M188OX; K199; C201CM) |
| radixin isoform a (Rdx) | (K209) (K211) (K212) (K335) |
| serine/threonine-protein phosphatase 2A catalytic subunit beta isoform (Ppp2cb) | (C20CM; K21) (K41) |
| SUN domain-containing protein 1 isoform 1 (Sun1) | (K160) |
| SUN domain-containing protein 2 isoform 1 (Sun2) | (K124; N126DIA) |
| ubiquitin-60S ribosomal protein L40 (Uba53) | (K11) |
| vimentin (Vim) | (K188) (K188; M193OX) (K282) |
K: Ubiquitinated Lysine Residue; MOX: Oxidized Methionine Residue; NDIA: Asparagine Residue Deamidation; QDIA: Glutamine Residue Deamination; CCM: Cystine Residue Carbamidomethyl Modification
Literature mining for PH association with top proteins.
| Protein | PH Association | Reference |
|---|---|---|
| Calmodulin 1 | • ↓ Calm1 association with eNOS in intrapulmonary arteries from hypoxic prenatal sheep | Liu J, et al. 2009 |
| • ↓ Calm1 association with eNOS in pulmonary arteries from hypoxic rats | Murata T, et al. 2002 | |
| Caveolin-1 | • progressive ↓ in Cav1 in monocrotaline (MCT)-induced rat PH model | Huang J, et al. 2012 |
| • ↑ Cav1 expression in pulmonary artery SMC associated with neointima formation in MCT rat and PH patients | Huang J, et al. 2015 | |
| • Cav1 mutations associated with familial and idiopathic PAH | Austin ED, et al. 2012 | |
| • predicted Cav1 loss-of-function mutations associated with familial PAH | Desai AA. 2012 | |
| • ↑ Cav1 association with eNOS in pulmonary arteries from hypoxic rats | Murata T, et al. 2002 | |
| • ↑ Cav1 association with eNOS in intrapulmonary arteries from hypoxic prenatal sheep | Liu J, et al. 2009 | |
| Profilin-1 | • ↑ Pfn1 expression in MCT rat model of PAH | Dai YP, et al. 2006 |
| Hematopoietic progenitor cell antigen CD34 | • ↑ Cd34 expression in PH patient pulmonary artery EC | Müller AM, et al. 2002 |
| • ↑ Cd34 expression association with ireversible lesions in PAH patient pulmonary artery | Huang H, et al. 2011 | |
| Ephrin type-A receptor 2 | • ↓ Epha2 expression assiciated with worse outcomes in hypoxic-sugen PAH mouse model | Rhodes CJ, et al. 2015 |
| Integrin-linked protein kinase | • ↑ Ilk in distal PASMC from PAH patients and pulmonary artery from rat sugen-hypoxia PAH model | Kudryashova TV, et al. 2016 |
| Cell division control protein 42 homolog isoform 1 | • ↑ Cdc42 activity in hypoxic pulmonary artery myocytes | Fediuk J, et al. 2014 |
| • ↑ Cdc42 expression in lungs of chronic hypoxia mouse | Pi L, et al. 2018 | |
| • ↓ Cdc42 in pericytes purified from the PAH patient lung | Yuan K, et al. 2014 | |
| GTPase KRas | • ↑ Kras activity associated with PAH development secondary to lung cancer | Pullamsetti SS, et al. 2017 |
| Ras-related C3 botulinum toxin substrate 1 | • ↑ Rac1 expression in arteries from IPAH patients | Laumanns IP, et al. 2009 |
| • ↑ Rac1 activity in lungs and PASMC from chronic hypoxia PH mouse model | Yu M, et al. 2012 | |
| • ↑ Rac1 activity in lung from BMP2 knock down mouse model of PAH | Johnson JA, et al. 2012 | |
| • ↓ Rac1 activity in PAEC from chronic hypoxia piglets | Wojciak-Stothard B, et al. 2006 | |
| Transforming protein RhoA | • ↑ RhoA activity in PAEC from chronic hypoxia piglets | Wojciak-Stothard B, et al. 2006 |
| • ↑ RhoA expression in arteries from IPAH patients | Laumanns IP, et al. 2009 | |
| • ↑ RhoA activity in lung from BMP2 knock down mouse model of PAH | Yasuda T, et al. 2011 | |
| • ↑ RhoA activity in platelets from PH patients | Yaoita N, et al. 2014 |
Fig. 5.Gene ontology enrichment in proteins not involved in PH associated pathways. DAVID (Database for Annotation, Visualization and Integrated Discovery) was used to generate a list of gene ontologies. Each bar represents the percent of analyzed proteins associated within the indicated pathway.
Fig. 6.Validation of selected proteins by western blotting. A) Annexin A2 (n = 13), B) Profilin-1 (n = 11), C) NOSTRIN (n = 12,13), and D) Fhl1 (n = 11,10) protein levels in mouse lung (mLung) were normalized to β-actin (p<0.05; * compared to Normoxia). Error bars = SEM. Anxa2 = Annexin A2, Pfn-1 = Profilin-1, NOSTRIN = Nitric Oxide Synthase TRaffic INducer, and Fhl1 = Four and a half LIM domain 1.